Transforming protein RhoA

Cells Move in Groups Differently Than They Do When Alone

Retrieved on: 
Wednesday, December 13, 2023
NYU Langone Health, National Institutes of Health, Cell biology, Tissue, Protein, Multimedia, Transforming protein RhoA, Zebrafish, Movement, Biology, Bacteria, NYU, Cancer, Human, Doctor of Philosophy, Current Biology, Cell, American Heart Association, Mobile phone

NEW YORK, Dec. 13, 2023 /PRNewswire/ -- A protein that helps generate the force needed for single cells to move works differently in cells moving in groups, a new study shows.

Key Points: 
  • NEW YORK, Dec. 13, 2023 /PRNewswire/ -- A protein that helps generate the force needed for single cells to move works differently in cells moving in groups, a new study shows.
  • Zebrafish are a major model in the study of development because they are transparent and share cellular mechanisms with humans.
  • The current study found that the cells in the primordium instead activate RhoA in pulses in the front of the cells where it does two jobs.
  • "The machinery suggests that the movement of single cells and groups of cells is similar, but that RhoA contributes to that machinery differently in each case.

Orange Grove Bio Subsidiary Awarded $2.05 Million SBIR Phase II Grant to Advance Development of Novel Platelet Preservation Technology

Retrieved on: 
Thursday, September 28, 2023
Heart, Maintenance, Drug development, University, Therapy, AUC, Regeneron Pharmaceuticals, PNC Center, Harvard University, SBIR, Biotechnology, University of California, San Francisco, National Heart, Lung, and Blood Institute, Pathology, OGB, Refrigeration, Head, American Academy, Research, Temperature, Lung, PNC, Autoimmunity, Bangladesh Technical Education Board, Eli Lilly, National academy, Publishing, National Academy of Medicine, Lilly, Patient, UCSF, Risk, Immune system, Small Business Innovation Research, G04, Drug discovery, Science, Transforming protein RhoA, Immunology, Health, NIH, Technology transfer, Allen Institute, Pharmaceutical industry, Vaccine, MBBS

Preservation Bio seeks to transform blood banking for donated platelets with an ex vivo additive that protects platelets from the damage normally caused by refrigeration.

Key Points: 
  • Preservation Bio seeks to transform blood banking for donated platelets with an ex vivo additive that protects platelets from the damage normally caused by refrigeration.
  • The SBIR grant will help fund Preservation Bio’s continued advancement of G04 through preclinical development and toward the clinic.
  • With more than eight million platelet units donated yearly, the global platelet market is estimated to be at least $4 billion.
  • Orange Grove Bio fosters strong relationships with technology transfer offices outside of the traditional medical technology hubs of Boston and San Francisco.

Nitrase Therapeutics Presents Preclinical Data on the Role of Enzymatic Nitration in Oncology at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023
AACR, Mitochondrion, Neoplasm, Overalls, Survival, Enzyme, Cancer, PAK4, Cell, RNA, Human Protein Atlas, Protein, The Cancer Genome Atlas, BAX, Annual general meeting, Escape Room, Liver, Transforming protein RhoA, Therapy, TCGA, Vaccine

“Therefore, targeted inhibition or degradation of the specific nitrase, or of the nitrated protein itself, could be a promising therapeutic approach in cancer.

Key Points: 
  • “Therefore, targeted inhibition or degradation of the specific nitrase, or of the nitrated protein itself, could be a promising therapeutic approach in cancer.
  • BAX is a specific substrate for Nitrase #11, and its cytochrome C release from the mitochondria is reduced upon nitration.
  • Utilizing The Cancer Genome Atlas (TCGA) RNA expression data and The Human Protein Atlas, nitrases were screened for association with overall survival in relation to nitrase RNA expression.
  • Additionally, several nitrases were negatively prognostic for kidney cancer or liver cancer.

Nitrase Therapeutics Presented Data on Role of Novel Nitrases in Regulating Known and Important Cancer Targets at EORTC-NCI-AACR Symposium

Retrieved on: 
Monday, October 31, 2022
EORTC, Investment, The Michael J. Fox Foundation, Nitration, Therapy, MJFF, Transforming protein RhoA, Cancer, CA, GLOBE, Survival, Protein, Sofinnova, Enzyme, Bristol Myers Squibb, CD3, Pharmaceutical industry, PAK4

Nitration of these proteins by specific company-identified nitrases was shown to regulate the activity of the nitro-substrates.

Key Points: 
  • Nitration of these proteins by specific company-identified nitrases was shown to regulate the activity of the nitro-substrates.
  • This unlocks a new treatment approach in cancer developing therapeutics that inhibit the specific nitrases involved in the nitration of oncogenic proteins.
  • The company has identified over 25 nitrases to-date and showed that several play a potential role in cancer.
  • The company has identified the nitro-substrates, the proteins modified by nitrases, for several nitrases that act as important contributors to the onset and progression of cancer.

Marana Group® Acquired by TMK Worldwide, LLC

Retrieved on: 
Monday, March 21, 2022
Family, Principal, Leadership, Government, Health, Growth, Transforming protein RhoA, LLC, Technology, Workflow, Solution, Education, Melissa, TMK, Renewable energy

(TMK) announced March 5, 2022, that it has acquired Marana Group.

Key Points: 
  • (TMK) announced March 5, 2022, that it has acquired Marana Group.
  • Marana Group, originally founded in 1977 under the name Lake Michigan Mailers, Inc. is a premier provider of technology solutions servicing organization throughout the United States, Canada, Europe, and Australia.
  • TMK investors selected Marana Group from a broad pool of candidate companies because of its rich history of service to a diverse client base, its integrated workflow and technology platform.
  • Not only is Marana Group capable of supporting the most complex programs, but its continuous improvement will create costs leadership throughout the workflow," said Melissa Nisbet, Principal of TMK Worldwide, LLC.

BridGene Biosciences' IMTAC ™ Small Molecule Discovery Platform Featured in Multiple Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Thursday, October 7, 2021
SAR, TEAD, Sunitinib, SAN, Transforming protein RhoA, Drug discovery, Conference, Liposarcoma, TCGA, Cell, Nm, Protein, Glioblastoma, Diagnosis, Cancer, Immortalised cell line, NF2, Education, American Association for Cancer Research, Entrepreneurship, The Cancer Genome Atlas, Factor X, ELISA, WDR5, AACR, GTPase, Stomach, CDH1, Gene expression, CEO, Mesothelioma, MLL1, American Association, Association, IC50, Disease, Patient, Science, DGC, Research, Technology, Pharmaceutical industry, Vaccine, Fine chemical, Mobile phone

The presentations detail the company's proprietary small molecule discovery platform, IMTACTM (Isobaric Mass Tagged Affinity Characterization) and its use in BridGene's latest discovery of therapeutic candidates and the identification of new targets for approved small-molecule drugs.

Key Points: 
  • The presentations detail the company's proprietary small molecule discovery platform, IMTACTM (Isobaric Mass Tagged Affinity Characterization) and its use in BridGene's latest discovery of therapeutic candidates and the identification of new targets for approved small-molecule drugs.
  • "This is among the most prominent scientific gatherings addressing drug discovery and molecular targets.
  • Overall, our presentations describe our IMTAC platform technology and its capabilities, the discovery of novel small-molecule inhibitors for undruggable targets, and the identification of previously unknown targets for approved small-molecule drugs."
  • BridGene used the IMTAC platform to screen its unique covalent library against live-cell proteomes and discovered small-molecule ligands for WDR5.